1Lipton RB, Stewart WF, Scher AI. Epidemiology and economic impact of migraine [J]. Curr Med Res Opin, 2001, 17 (Suppl 1): S4-S12.
2Steiner TJ, MacGregor EA, Davies PTG. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type, cluster and medication overuse headache [M]. British Association for the Study of Headache, 3rd edn. 2007: I-52.
3Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edn [J]. Cephalalgia, 24 (Suppl 1): S1-S160.
4Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force [J]. Eur J Neurol, 2009, 16 (9): 968-981.
5Monteith TS, Goadsby PJ. Acute migraine therapy: new drugs and new approaches [J]. Curr Treat Options N eurol, 2011, 13(1):1-14.
6Azzopardi TD, Brooks NA. Oral metoclopramide as an adjunct to analgesics for the outpatient treatment of acute migraine [J]. Ann Pharrnacother, 2008,42 (3): 397-402.
7Olesen J, Diener HC, Schoenen J, et al. No effect of eletriptan administration during the aura phase of migraine [J]. Eur J Neurol, 2004,11 (10): 671-677.
8Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT (1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials [J]. Lancet, 2001, 358 (9294): 1668-1675.
9Smith TR, Sunshine A, Stark SR, et al. Sumatriptan and naproxen sodium for the acute treatment of migraine [J] . Headache, 2005, 45 (8): 983-991.
10Calabresi P, Galletti F, Rossi C, et al. Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms [J] . Trends Pharrnacol Sci, 2007, 28 (4): 188-195.
